What factors drove the changes in Stereotaxis's revenue and profit?

Did Stereotaxis beat or miss consensus estimates last quarter?

What does Stereotaxis do and what are its main business segments?

What is the revenue and EPS growth rate for Stereotaxis year over year?

What were the key takeaways from Stereotaxis’s earnings call?

What is the market's earnings forecast for Stereotaxis next quarter?

What is Stereotaxis's gross profit margin?

What is Stereotaxis's latest dividend and current dividend yield?

- **FDA Approval Milestone**: GenesisX system approved in the U.S., positioning for premium pricing and expanded adoption in 2026.
- **Catheter Revenue Surge**: MAGiC Sweep generated $300K in 2 months, with strong clinical adoption and potential for halo effect on robotic systems.
- **2026 Growth Outlook**: Guided for >$10M quarterly revenue, driven by GenesisX launches and catheter adoption, with a balanced focus on margins and profitability.
- **Digital Surgery Innovation**: Synchrony system CE Marked, targeting $2M+ in first-year revenue and future SaaS growth.

**【CEO Summary】**
- **Dual Growth Strategy**: Focused on scaling robotic system sales (Genesis and GenesisX) and building a high-margin recurring revenue business through proprietary catheters.
- **GenesisX Launch**: Received FDA approval for GenesisX, positioning it as a premium system with a limited launch in Europe and U.S. Full launch expected in early 2026. Q3 saw 2 Genesis orders from European hospitals, adding to a $10M+ backlog.
- **Catheter Success**: MAGiC Sweep generated $300K in U.S. revenue within 2 months, with only 25% of robotic accounts adopting it. MAGiC ablation catheter approved in Europe, awaiting U.S. FDA approval.
- **Pipeline Momentum**: Synchrony digital cath lab system received CE Mark, targeting $2M+ in first-year revenue. Collaboration with CardioFocus for robotic PFA system progressing toward clinical trials.

**【CFO Financial Commentary】**
- **Q3 2025 Results**: Total revenue $7.5M (15% YoY growth), with system revenue $1.9M and recurring revenue $5.6M. Gross margin 55%, recurring margin 67%.
- **Cash Position**: $10.5M in cash, with $14.5M post-upcoming registered direct financing. Negative free cash flow of $4.2M, consistent with prior year.
- **Q4 Guidance**: Revenue >$9M (20%+ YoY growth), with system revenue ~$3M and recurring >$6M.

**【Q&A Highlights】**
- **GenesisX Sales**: Expected to outpace Genesis orders post-full launch, with pricing at a premium. Non-EP applications (e.g., neurovascular) may drive new accounts in 2026.
- **Commercial Team Expansion**: Clinical team to grow to 1:1 rep-to-hospital ratio for catheters; capital team to add dedicated reps for GenesisX scaling.
- **MAGiC Approval Timeline**: FDA review progressing well, with potential U.S. approval in line with prior guidance. MAGiC Sweep Europe launch pending regulatory approvals.


Stereotaxis, Inc. (STXS) Q3 2025 Earnings Call Transcript

- **Breakthrough Revenue Growth**: Q2 2025 revenue up 95% YoY to $8.8M, driven by GenesisX and MAGiC catheter launches. 
- **Innovative Product Pipeline**: FDA-cleared MAGiC Sweep and CE-cleared MAGiC ablation catheters set to boost recurring revenue; GenesisX robot installations beginning in Europe. 
- **Strategic Financing**: $12.5M equity raise strengthens balance sheet for sales force expansion and product launches. 
- **Market Expansion**: Targeting 1 clinical rep per hospital to accelerate adoption of high-margin catheters, with potential $2K+ per procedure revenue.

**【CEO Summary Section】**
- **Strategic Innovations**: Focused on four pillars—robot accessibility, catheter ecosystem, interventional devices, and AI-driven digital surgery. GenesisX, a compact robot, received CE Mark and nearing FDA approval, with first commercial installation in Europe expected soon. MAGiC ablation catheter contributed $200K+ in Q2 European revenue, used in 30% of EU accounts across various arrhythmias. MAGiC Sweep, a high-density mapping catheter, cleared in the U.S. and set to launch this quarter, promising $2K+ per procedure revenue. Imagine catheter submission pending, targeting endovascular surgery expansion. Digital platform Synchrony/SynX nearing FDA clearance for OR connectivity and AI integration.

**【CFO Financial Commentary】**
- **Q2 2025 Results**: Revenue $8.8M (95% YoY growth), with $3M system and $5.8M recurring revenue. Gross margin 52% (68% recurring). Operating loss $4M, net loss $3.8M. Secured $12.5M equity financing, boosting cash to $18.8M. Guidance: Full-year double-digit revenue growth, system revenue $2-3M/Q, recurring scaling to $7M by Q4.

**【Q&A Highlights】**
- **Sales Force Expansion**: Planning to increase clinical reps to 1 per hospital (currently 1/3-4 hospitals) as MAGiC/MAGiC Sweep adoption grows. U.S. and Europe to get dedicated capital teams for GenesisX launch. 
- **MAGiC Usage**: 30% of EU accounts using MAGiC in Q2, across SVT, VT, AF, and flutter. MAGiC Sweep U.S. launch expected this quarter, targeting 70%+ procedure usage. 
- **Regulatory Progress**: MAGiC Sweep CE Mark pending; Imagine catheter clearance expected this quarter. FDA MAGiC approval anticipated late 2025 after sterility/biocompatibility reviews.

Stereotaxis, Inc. (STXS) Q2 2025 Earnings Call Transcript

- **Revenue Growth**: 9% YoY to $7.5M, driven by 28% recurring revenue growth.
- **Catheter Success**: Map-iT U.S. sales +30% QoQ; MAGiC Europe Q2 revenue >$200K.
- **Robot Momentum**: GenesisX first purchase order; MAGiC Sweep/EMAGIN approvals Q3.
- **China Risk**: Regulatory approval secured, but macro delays viewed as upside.
- **Margins**: Recurring margins to recover to 75%+ by Q3.


**【CEO Commercial Updates】**
- Q1 2025 revenue grew 9% YoY to $7.5M, driven by recurring catheter sales and system installations.
- **Map-iT Catheters**: U.S. sales grew 30% QoQ, with 30% of U.S. robotic customers initiating purchases. Global sales exceeded $1M.
- **MAGiC Catheter**: European approval achieved; 20% of EU hospital customers have initiated sales, with Q2 revenue expected to reach $200K+.
- **GenesisX Robot**: First purchase order received, with soft launch at major conferences (EHRA, HRS). Full commercial launch pending U.S. FDA approval.

**【CFO Financial Highlights】**
- Q1 2025: 
  - Total revenue: $7.5M (9% YoY growth)
  - Recurring revenue: $5.5M (28% YoY growth)
  - System revenue: $2.0M (54% YoY growth)
  - Gross margin: 54% (68% recurring, 15% systems)
- **Margins**: Recurring margins temporarily depressed by acquisition accounting (75% pre-acquisition → 68% now → expected 75%+ by Q3)
- **Cash Flow**: Negative free cash flow of $1.8M (vs. $2.3M prior year), with $10.7M cash on hand.

**【Q&A Key Takeaways】**
- **Europe**: Expect MAGiC Europe revenue to reach $1M/Q4 by year-end. Genesis system orders steady (~1-2/Q).
- **U.S.**: MAGiC FDA approval expected H2 2025; GenesisX U.S. launch contingent on FDA approval.
- **China**: Regulatory approval secured, but macro uncertainty delays orders. Viewed as upside.
- **New Products**: 
  - MAGiC Sweep and EMAGIN guidewires expected EU/U.S. approval Q3.
  - GenesisX FDA feedback narrowing to final questions; approval eyed summer 2025.


Stereotaxis (STXS)-12 May 25-2025 Q1 Earnings call transcript

- **Robot Commercialization**: GenesisX poised for Q3 2025 Europe launch, US approval pending.\
- **Catheter Growth**: MAGIC Europe sales ramping to $1M/Q, MAGIC Sweep to add 5x disposable revenue.\
- **New Markets**: EMAGIN vascular catheter targeting neurointerventions, with Q3 2025 approvals.\
- **China Hurdles**: Regulatory and macroeconomic delays may limit 2025 system sales.\
- **Financial Outlook**: 2025 revenue flat vs 2024, with 2026 breakout potential from GenesisX and EMAGIN adoption.

**【CEO Strategic Overview】**
- **GenesisX Robot Progress**: Received CE Mark in Europe, submitted for US FDA approval. First commercial installation in Europe expected Q3 2025, with US launch in H2 2025.\
- **Catheter Portfolio Expansion**: MAGIC ablation catheter approved in Europe (Q1 2025 sales), MAGIC Sweep high-density mapping catheter submitted for 510(k) (Q3 2025 approvals).\
- **New Indications**: EMAGIN vascular catheter submitted for regulatory approval, targeting neurointerventions, RDN, and complex PCI.\
- **China Expansion**: Partner MicroPort approved Genesis system; pipeline of 12+ hospitals, though delayed by macroeconomic challenges.\
- **Digital Surgery Platform**: SynX system to enable AI-driven cath lab connectivity, with H2 2025 commercial launch.\

**【CFO Financial Highlights】**
- **Q4 2024 Results**: Total revenue $6.3M (+39% YoY), system revenue $1.4M, recurring revenue $4.9M (includes APT contribution).\
- **Full Year 2024**: Revenue $26.9M, system revenue $8.6M, recurring revenue $18.3M. Gross margin 54%, adjusted operating loss $12.8M.\
- **2025 Guidance**: System revenue $2-3M/Q, recurring revenue growing to $7M/Q4. Positive free cash flow expected with reduced cash burn.\

**【Q&A Key Takeaways】**
- **MAGIC US Approval**: PMA review ongoing, with Q3 2025 approval target.\
- **China Risk**: Regulatory and reimbursement delays may impact 2025 sales.\
- **EMAGIN Strategy**: Focus on neurointerventions and RDN for initial commercial traction.\
- **System Backlog**: $15.2M entering 2025, but conservative guidance due to execution uncertainty.

STXS

STXS fundamentals

Earnings Call

You can ask Aime